-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech Says Phase 2 DURIPANC Topline Results Expected In Q1 2027, With Additional Clinical And Immune-Response Analyses Anticipated In Q3 2027

Benzinga·11/05/2026 14:22:08

-SEC Filing